Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke

European Journal of Epidemiology

Volumn 31, Issue 4, 2016, Pages 415-426

  Wald, Nicholas J ^a   Luteijn, Johannes Michiel ^a   Morris, Joan K ^a   Taylor, David ^b   Oppenheimer, Peter ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c CHRIST CHURCH   (United Kingdom)

Author keywords

Cardiovascular diseases; Cost benefit analysis; Myocardial infarction; Polypill; Primary prevention; Stroke

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; SIMVASTATIN; ACETYLSALICYLIC ACID; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; CANCER PREVENTION; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; FEMALE; HEALTH PROGRAM; HEART INFARCTION; HUMAN; MALE; PATIENT COMPLIANCE; POLYPHARMACY; PRIMARY PREVENTION; SENSITIVITY ANALYSIS; SURVIVAL TIME; UNITED KINGDOM; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; ECONOMICS; MARKOV CHAIN; MIDDLE AGED; MYOCARDIAL INFARCTION; QUALITY ADJUSTED LIFE YEAR; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMLODIPINE; ASPIRIN; CARDIOVASCULAR AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COST-BENEFIT ANALYSIS; HUMANS; HYDROCHLOROTHIAZIDE; LOSARTAN; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYPHARMACY; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; SIMVASTATIN; STROKE; UNITED KINGDOM;

EID: 84960122817     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-016-0122-1     Document Type: Article

References (44)

1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168:934–45.
2. Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database. BMJ Open. 2011;1:e000269.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. BMJ. 2003;326:1419–23.
4. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7:e41297.
5. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427–31.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
8. Wald NJ, Morris JK. Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. Eur J Epidemiol. 2014;29:605–12.
9. Wald NJ, Morris JK. Erratum: quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. Eur J Epidemiol. 2015;30(6):521–3.
10. Office for National Statistics. Population estimates for UK, England and Wales, Scotland and Northern Ireland, 2010. http://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland.
11. Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006;92:1384–9.
12. Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing. 2009;38:27–32.
13. HM Treasury. GDP deflators at market prices, and money GDP: March 2015 (ONS quarterly national accounts), vol 20152015.
14. Wald DS, Wald NJ. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J Eval Clin Pract. 2012;18:612–5.
15. Allender S, Peto V, Scarborough P, Kaur A, Rayner M. coronary heart disease statistics: British Heart Foundation Health Promotion Research Group. Oxford: Department of Public Health, University of Oxford; 2008.
16. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.
17. HM Treasury. Public expenditure statistical analyses. London: HM Treasury; 2015.
18. Wald NJ, Oppenheimer P. Discounting the value of life. J Med Screen. 2011;18:1.
19. The Patient Protection and Affordable Care Act. PL 111-1483.23.2010.
20. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26:733–44.
21. Wald NJ, Luteijn JM, Morris JK. Starting the polypill: the use of a single age cut-off in males and females. J Med Screen (in press).
22. Wald NJ, Simmonds M, Morris JK. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One. 2011;6:e18742.
23. Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation. 2005;112:2301–6.
24. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52c–60c.
25. OECD. Health at a glance 2013: OECD indicators. OECD Publishing; 2013. http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf.
26. Prescribing and Primary Care Health and Social Care Information Centre. Prescriptions dispensed in the community. England 2003–2013. Health and Social Care Information Centre; 2014. http://www.hscic.gov.uk/searchcatalogue?productid=14988&q=title%3a%22Prescriptions+Dispensed+in+the+Community%22&sort=Relevance&size=10&page=1.
27. Office for National Statistics. Mortality statistics: deaths registered in England and Wales (series DR), 2013. http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsregisteredinenglandandwalesseriesdrreferencetables.
28. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BW, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
29. Sheldon TA. Discounting in health care decision-making: time for a change? J Public Health Med. 1992;14:250–6.
30. Wald NJ, Oppenheimer P. Discounting financial costs and health benefits in public health programmes. J Med Screen 2016. doi:10.1177/0969141315626190.
31. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570–6.
32. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39.
33. van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011;1:e000363.
34. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679–86.
35. Vos T, Carter R, Barendregt J, et al. Assessing cost-effectiveness in prevention (ACE–Prevention): final report. Melbourne: University of Queensland, Brisbane and Deakin University; 2010.
36. Desai N. A cardiovascular polypill. In: Garber S, Gates SM, Keeler EB et al., editors. Redirecting innovation in U.S. Health Care: options to decrease spending and increase value: case studies, vol 2015: Santa Monica: RAND Health. RR-308; 2014.
37. Garber S, Gates S, Keeler E, et al. Redirecting innovation in US healthcare: options to decrease spending and increase value. Case studies, vol RR-3082014.
38. Law M, Wald NJ, Morris JK. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1–106.
39. Series DH1 no.18-28. Mortality statistics: general Review of the Registrar General on deaths in England and Wales, 1985–1995. London: Office for National Statistics.
40. Office for National Statistics. Mortality statistics: deaths registered in England and Wales (series DR), 2010 http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsregisteredinenglandandwalesseriesdrreferencetables.
41. Office for National Statistics. Population estimates for UK, En Office for National Statistics gland and Wales, Scotland and Nothern Ireland, 2010. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-231847.
42. Smolina K, Wright FL, Rayner R, Goldacre M. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012;344:d8059. doi:10.1136/bmj.d8059.
43. HSE 2009: Vol 1. Chapter 5: blood pressure and hypertension. The Health and Social Care Information Centre.
44. Prescriptions Dispensed in the Community: England 2002–12. V1.0 30.07.2013. Prescribing and Primary Care Services, Health and Social Care Information Centre.